{"id":710,"date":"2023-06-02T16:03:29","date_gmt":"2023-06-02T16:03:29","guid":{"rendered":"https:\/\/eastmedia.lt\/concertai-caris-life-sciences-partneris-onkologiniams-tyrimams\/"},"modified":"2023-06-02T16:03:29","modified_gmt":"2023-06-02T16:03:29","slug":"concertai-caris-life-sciences-partneris-onkologiniams-tyrimams","status":"publish","type":"post","link":"https:\/\/easa.lt\/index.php\/2023\/06\/02\/concertai-caris-life-sciences-partneris-onkologiniams-tyrimams\/","title":{"rendered":"ConcertAI, Caris Life Sciences partneris onkologiniams tyrimams"},"content":{"rendered":"<p><img decoding=\"async\" src=\"https:\/\/www.mobihealthnews.com\/sites\/default\/files\/Oncology%20-%20GettyImages-1130151355_1.jpg\" \/><\/p>\n<div property=\"content:encoded\">\n<p dir=\"ltr\"><span id=\"docs-internal-guid-63605399-7fff-2beb-12d2-01d0af9d525d\">Sveikatos prie\u017ei\u016bros duomen\u0173 \u012fmon\u0117 <\/span>\u201eConcertAI\u201c paskelb\u0117 apie i\u0161pl\u0117st\u0105 partneryst\u0119 su \u201eCaris Life Sciences\u201c, kur bendrov\u0117s kartu sukurs duomen\u0173 baz\u0119, kad gaut\u0173 \u012f\u017evalg\u0173, kaip tobulinti tiksli\u0105j\u0105 medicin\u0105, klinikini\u0173 tyrim\u0173 valdym\u0105 ir terapin\u012f vystym\u0105si.  <\/p>\n<p dir=\"ltr\"><span id=\"docs-internal-guid-63605399-7fff-2beb-12d2-01d0af9d525d\">\u201eConcertAI\u201c yra realaus pasaulio duomen\u0173 ir dirbtinio intelekto \u012fmon\u0117, skirta sveikatos prie\u017ei\u016bros paslaug\u0173 teik\u0117jams ir gyvosios gamtos moksl\u0173 \u012fmon\u0117ms, o \u201eCaris Life Sciences\u201c si\u016blo vis\u0105 egzomo ir visos transkripto sek\u0105, kuri naudoja AI modeliavim\u0105 savo klinikin\u0117je ir genomin\u0117je duomen\u0173 baz\u0117je, kad pad\u0117t\u0173 tyr\u0117jams suprasti lig\u0173 molekulin\u012f sud\u0117tingum\u0105.<\/span><\/p>\n<p dir=\"ltr\"><span id=\"docs-internal-guid-63605399-7fff-2beb-12d2-01d0af9d525d\">Partneriai sukurs duomen\u0173 baz\u0119, kurioje bus panaudoti abiej\u0173 \u012fmoni\u0173 klinikiniai, molekuliniai ir multimodaliniai duomenys, kad mokslininkai ir biofarmacijos mokslininkai gal\u0117t\u0173 \u012fgyti \u012f\u017evalg\u0173 apie \u012f onkologij\u0105 orientuot\u0105 tiksli\u0105 medicin\u0105, klinikini\u0173 tyrim\u0173 valdym\u0105 ir terapin\u012f vystym\u0105.<\/span><\/p>\n<p dir=\"ltr\"><span id=\"docs-internal-guid-63605399-7fff-2beb-12d2-01d0af9d525d\">\u201eKurdami naujus mokslini\u0173 tyrim\u0173 i\u0161teklius populiacijos mastu, integruotus su pirmaujan\u010diomis technologijomis ir talentais, galime bendradarbiauti su akademiniais tyr\u0117jais ir biofarmacijos novatoriais, kad paspartintume nauj\u0173 \u012f\u017evalg\u0173 apie v\u0117\u017eio biologijos pagrindus, greitai perkeltume \u0161ias \u012f\u017evalgas \u012f klinik\u0105 ir \u012fgalintume naujas klinikines galimybes. pl\u0117tros metodai\u201c, &#8211; sak\u0117 dr. <\/span>Jeffas Eltonas, \u201eConcertAI\u201c generalinis direktorius, sak\u0117 parei\u0161kime.  \u201eGal\u0173 gale, palengvinus plataus masto prieig\u0105 prie tokio gylio ir masto duomen\u0173, be daugelio vie\u0161\u0173j\u0173 ar priva\u010di\u0173 iniciatyv\u0173, bus lengviau visiems v\u0117\u017eiu sergantiems pacientams, ypa\u010d tiems, kurie nepakankamai aptarnaujami ir turi nedaug dabartini\u0173 gydymo galimybi\u0173.<\/p>\n<p dir=\"ltr\"><strong><span id=\"docs-internal-guid-63605399-7fff-2beb-12d2-01d0af9d525d\">DIDESN\u0116 TENDENCIJA<\/span><\/strong><\/p>\n<p dir=\"ltr\"><span id=\"docs-internal-guid-63605399-7fff-2beb-12d2-01d0af9d525d\">Caris Life Sciences and ConcertAI <\/span>saus\u012f inicijavo savo partneryst\u0119, kad prisijungt\u0173 prie dviej\u0173 \u012fmoni\u0173 onkologijos paj\u0117gum\u0173, kad b\u016bt\u0173 pa\u017eang\u016bs terapiniai tyrimai ir vaist\u0173 k\u016brimas. <\/p>\n<p dir=\"ltr\"><span id=\"docs-internal-guid-63605399-7fff-2beb-12d2-01d0af9d525d\">ConcertAI yra SymphonyAI, didesn\u0117s dirbtinio intelekto \u012fmon\u0117s, apiman\u010dios kitus verslo sektorius, pavyzd\u017eiui, ma\u017emenin\u0117s prekybos ir finans\u0173, dalis.  2020 metais ji \u012fsigijo <\/span>vaizdo AI si\u016blanti \u201eTeraRecon\u201c, kuri dabar vadinama \u201eConcertAI\u201c \u012fmone. <\/p>\n<p dir=\"ltr\"><span id=\"docs-internal-guid-63605399-7fff-2beb-12d2-01d0af9d525d\">Per daugel\u012f met\u0173 \u012fmon\u0117 u\u017emezg\u0117 daugyb\u0119 partnerys\u010di\u0173, \u012fskaitant bendradarbiavim\u0105 su <\/span>\u201eJanssen Research &#038; Development\u201c, siekdama tobulinti studij\u0173 plan\u0105 ir \u012fvairinti klinikinius tyrimus, ir \u201eBristol-Myers Squibb\u201c ir \u201ePfizer\u201c remti tikslaus onkologinio gydymo tyrimus.<\/p>\n<p dir=\"ltr\"><span id=\"docs-internal-guid-63605399-7fff-2beb-12d2-01d0af9d525d\">Abi bendrov\u0117s per pastaruosius kelerius metus surinko did\u017eiules investicijas.  ConcertAI, anks\u010diau <\/span>\u201eConcerto HealthAI\u201c 2022 m. surinko 150 mln. USD C serijos finansavimo, pra\u0117jus vos dvejiems metams po to, kai u\u017ebaig\u0117 150 mln. USD bendr\u0105 B serijos finansavim\u0105.<\/p>\n<p dir=\"ltr\"><span id=\"docs-internal-guid-63605399-7fff-2beb-12d2-01d0af9d525d\">U\u017etikrintas \u201eCaris Life Sciences\u201c. <\/span>400 mln. USD skolos finansavimas sausio m\u0117n., tod\u0117l bendras kapitalas padidino daugiau nei 1,7 mlrd. USD.  2021 m. bendrov\u0117 u\u017edirbo 830 mln. USD augimo akcinio kapitalo, o 2020 m. gavo 235 mln. <\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Sveikatos prie\u017ei\u016bros duomen\u0173 \u012fmon\u0117 \u201eConcertAI\u201c paskelb\u0117 apie i\u0161pl\u0117st\u0105 partneryst\u0119 su \u201eCaris Life Sciences\u201c, kur bendrov\u0117s kartu sukurs duomen\u0173 baz\u0119, kad gaut\u0173 \u012f\u017evalg\u0173, kaip tobulinti tiksli\u0105j\u0105 medicin\u0105, klinikini\u0173 tyrim\u0173 valdym\u0105 ir terapin\u012f vystym\u0105si. \u201eConcertAI\u201c yra realaus pasaulio duomen\u0173 ir dirbtinio intelekto \u012fmon\u0117, skirta sveikatos prie\u017ei\u016bros paslaug\u0173 teik\u0117jams ir gyvosios gamtos moksl\u0173 \u012fmon\u0117ms, o \u201eCaris Life Sciences\u201c [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":711,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"class_list":["post-710","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-bendri"],"_links":{"self":[{"href":"https:\/\/easa.lt\/index.php\/wp-json\/wp\/v2\/posts\/710","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/easa.lt\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/easa.lt\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/easa.lt\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/easa.lt\/index.php\/wp-json\/wp\/v2\/comments?post=710"}],"version-history":[{"count":0,"href":"https:\/\/easa.lt\/index.php\/wp-json\/wp\/v2\/posts\/710\/revisions"}],"wp:attachment":[{"href":"https:\/\/easa.lt\/index.php\/wp-json\/wp\/v2\/media?parent=710"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/easa.lt\/index.php\/wp-json\/wp\/v2\/categories?post=710"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/easa.lt\/index.php\/wp-json\/wp\/v2\/tags?post=710"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}